Dupixent Lawsuit Claims for CTCL & T-Cell Lymphoma Nationwide
Pharmaceutical Litigation
A Dupixent lawsuit alleges that drug manufacturers Sanofi and Regeneron Pharmaceuticals sold the eczema biologic dupilumab without warning patients and doctors that it can cause or accelerate cutaneous T-cell lymphoma (CTCL) or related cancers. Potential claims were consolidated into MDL 3180 on June 4, 2026. Every Dupixent claim is filed individually, not as a class action. This means each plaintiff keeps their own individual lawsuit and settlement. The consolidated litigation just helps streamline discovery and other legal processes.
If you were diagnosed with CTCL after using Dupixent, contact our law firm for a free consultation. We’re reviewing Dupixent cancer lawsuit case reports nationwide.
Types of Cases
Dupixent Lawsuit Update: MDL No. 3180
The Judicial Panel on Multidistrict Litigation centralized Dupixent cases in one federal court on June 4, 2026, before Judge Zahid N. Quraishi in the District of New Jersey. The defendants are the medication manufacturers Sanofi and Regeneron, along with Genzyme Corporation, which operates under the Sanofi-Aventis corporate umbrella.
The full text of the JPML transfer order creating MDL 3180 is public.
Fifteen legal actions and seven potential tag-along actions were pending across twelve districts at centralization. The Judicial Panel on Multidistrict Litigation chose the New Jersey federal court on the evidence: Sanofi and Regeneron Pharmaceuticals are either headquartered in the district or have corporate offices nearby, making it easier to review evidence locally.
The Judicial Panel on Multidistrict Litigation identified three safety questions driving the consolidated litigation:
- Do studies suggest a link between Dupixent use and an increased risk of cutaneous T-cell lymphoma and common subtypes?
- When should Sanofi and Regeneron have known their drug caused the increased risk for developing CTCL or related cancers?
- Did Sanofi and Regeneron Pharmaceuticals provide adequate warnings to patients and doctors?
Our law firm is handling ongoing Dupixent litigation through our drug injury and defective medical device practice, filed as product liability claims against manufacturers.
| Item | Detail |
|---|---|
| MDL Number | MDL No. 3180 |
| Transfer Date | June 4, 2026 |
| District | U.S. District Court for the District of New Jersey |
| Judge | Judge. Zahid N. Quraishi |
| Defendants | Genzyme Corporation, Regeneron Pharmaceuticals, and Sanofi-Aventis U.S. LLC |
| Legal Actions at Centralization | 15 pending actions across 12 districts, plus 7 potential tag-along actions |
| Current Pending Actions | 26 pending actions as of October 7, 2026, according to the JPML's latest pending-MDL report |
| Injuries Currently Included | Cutaneous T-cell lymphoma and T-cell lymphoma subtypes |
| Class Action Status | Not a class action. Individual lawsuits coordinated for pretrial proceedings. |
Dupixent Cancer Lawsuit: What the Medical Research Shows
Nobody has proven that Dupixent may cause a cancer called cutaneous T-cell lymphoma. That’s not what Dupixent lawsuits allege. The Dupixent lawsuits claim that Sanofi and Regeneron Pharmaceuticals had enough information to adequately warn users years ago, and the manufacturers failed to warn patients and doctors alike. Because they failed to warn doctors, patients weren’t given the chance to weigh the increased risk of CTCL that the FDA itself is now reviewing.
Is There a Dupixent Recall?
The FDA listed Dupixent with the potential signal of cutaneous T-cell lymphoma in its October to December 2024 quarterly report, with the table current as of August, 2026. The agency is evaluating the need for regulatory action.
That is not a recall, a warning letter, or a label change. It is the FDA saying the case reports crossed a threshold worth reviewing.
The Link Between Dupixent and Lymphoma Risk Drug Manufacturers Failed to Warn About
One of the major problems with the FDA approval process is that drug manufacturers can fund their own research. Regeneron Pharmaceuticals and Sanofi funded most of the original studies published. When the FDA first approved Dupixent, it was based on their own research. The studies led by the drug manufacturers were consistently reassuring:
- The Phase III trials reported that Dupixent (dupilumab) administration “provides rapid and sustained efficacy and is generally well tolerated.”
- Long-term moderate to severe eczema safety data by Sanofi Aventis reinforced that the drug “does not require initial or ongoing blood testing.”
- In pediatric asthma trials for younger ages 6 to 11, the drug manufacturers described outcomes as “generally safe.”
- The Phase 3 pediatric trial for eosinophilic esophagitis reported dupilumab use as “generally safe.”
- In 24-week prurigo nodularis trials, company-funded researchers reported consistency with prior safety findings.
Most Recent Research for Dupixent and Cutaneous T-Cell Lymphoma (CTCL)
The concerns aren’t that studies published by these companies were wrong. It’s that the companies failed to warn patients about a possible connection to a future cancer diagnosis.
Design issue | Why it matters to a Dupixent lawsuit |
|---|---|
Short duration | Many trials ran 16 to 24 weeks, too short to research even early-stage CTCL symptoms. |
Narrow populations | Higher-risk patients were conveniently excluded, so the trial group didn’t even include the typical patient who would take Dupixent. |
Safety framing | Press releases emphasized a “consistent safety profile” without detailed risk disclosure. |
No monitoring required | Sanofi has maintained that no baseline or ongoing testing is needed. |
Selective reporting | Later findings weren’t reflected back into the early safety picture. |
Consider the scale of the mismatch. The pivotal asthma trial randomized 1,902 patients over 52 weeks and measured exacerbation rates and lung function. That is a well-run study answering a completely different question than whether a rare skin cancer shows up five years later.
Most of the safety questions came from independent researchers. A population-based cohort study published by Hasan and colleagues found that Dupixent (dupilumab) used for eczema was associated with an increased risk of cutaneous T-cell lymphoma.
Researchers then went to the FDA’s adverse event data. One pharmacovigilance analysis identified 167,811 dupilumab case reports submitted between 2017 and 2023. 113 case reports involved cutaneous T-cell lymphoma. The researchers found that Dupixent patients had the highest reporting rate of cutaneous T-cell lymphoma (CTCL) compared to all other medications in the biologic subtype.
A broader review examined roughly 465,075 adverse event reports associated with Dupixent use across the same period and identified 2,071 case reports of patients diagnosed with CTCL.
The same recent study producing the higher risk of CTCL found no increased risk for non-CTCL lymphoma diagnosis or for other skin cancers. This is a major reason we’re excluding Dupixent cases involving melanoma, basal cell carcinoma, or B-cell lymphoma for what’s being legally reviewed at this stage of the Dupixent litigation.
The Two Explanations For the Cutaneous T-Cell Lymphoma Links to Dupixent (Dupilumab)
Accordion Content
Causation. Dupixent blocks part of the immune signaling pathway. The unblocked signal can reach a receptor that’s overactive in cutaneous T-cell lymphoma (CTCL) or related cancers. This can give the cancer room to grow slowly.
Unmasking. The cutaneous T-cell lymphoma was already there, hiding under what was diagnosed as severe eczema. Once the drug triggered inflammation suppression, the underlying lymphoma became visible.
Notice that both theories describe a real injury. If patients take Dupixent for eczema, asthma, or other conditions while an undiagnosed lymphoma moves to more advanced cases, the harm from worsening CTCL is in the delayed diagnosis. The question is still whether Sanofi and Regeneron provided adequate warnings based on what they knew.
Dupixent Lymphoma Lawsuit: Qualifying Diagnoses
Cutaneous T-cell lymphoma is a rare blood cancer that begins in the white blood cells that normally patrol the skin. Instead of circulating, the malignant T cells settle in the skin and produce scaly patches, plaques, and raised lesions that look and behave like an inflammatory disease. That resemblance to other inflammatory conditions is why so many Dupixent lymphoma lawsuits involve years of delayed diagnosis before anyone orders a biopsy.
Cutaneous T-cell lymphoma (CTCL) is routinely misdiagnosed as severe eczema, psoriasis, or contact dermatitis. Patients cycle through topical treatments, escalate to a biologic when nothing works, and the disease progression continues while the chart still records an inflammatory disease.
In advanced cases, the malignancy can cover most of the skin surface and spread to internal organs. Stage at diagnosis drives treatment burden, prognosis, and the value of a Dupixent lawsuit, which makes delayed diagnoses a legal issue as much as a medical one. That same pattern of a drug company failing to warn patients about a cancer risk runs through our work on Zantac claims and Taxotere injuries.
Which diagnoses qualify for filing a Dupixent lawsuit depends on where MDL 3180 currently draws the line:
Mycosis Fungoides: Most Common Type
Mycosis fungoides is the most common form of cutaneous T-cell lymphoma. It grows slowly and presents as scaly patches or plaques that can persist for years, which is why it is the presentation most often misread as treatment-resistant atopic dermatitis. The National Cancer Institute’s treatment summary covers staging and treatment in detail. Mycosis fungoides accounts for the majority of qualifying diagnoses in Dupixent lymphoma lawsuits filed to date.
Sézary Syndrome
Sézary syndrome is the aggressive leukemic form of CTCL, with widespread redness, severe itching, and malignant T cells circulating in the blood as well as living in the skin. Prognosis is poorer than early-stage CTCL, and the treatment burden is heavier, which is reflected in how Dupixent sézary syndrome claims are valued.
Other Cutaneous T-Cell Lymphoma (CTCL) Subtypes In The Dupixent Lymphoma Lawsuit: MDL 3180
Several less common cutaneous T-cell lymphoma subtypes fall within the current scope. If your pathology report names any of the following, your diagnosis is inside the litigation as it stands today:
- Lymphomatoid papulosis, which produces chronic papules or nodules that resemble lymphoma
- Primary cutaneous anaplastic large cell lymphoma, usually appearing as solitary or localized skin tumors
- Subcutaneous panniculitis-like T-cell lymphoma, which affects the fat layer beneath the skin and can mimic panniculitis
- Primary cutaneous gamma-delta T-cell lymphoma, an aggressive and fast-growing subtype
- Extranodal NK/T-cell lymphoma, which arises outside the lymph nodes
Can I File If I Was Diagnosed With a Non-CTCL Lymphoma?
When the Judicial Panel on Multidistrict Litigation created the MDL, the plaintiffs agreed litigation shouldn’t include: B-cell lymphoma, Hodgkin lymphoma, or other diseases that are not T-cell lymphomas. Plaintiffs argued for a wider scope covering peripheral T-cell lymphoma and systemic anaplastic large cell lymphoma.
The Judicial Panel on Multidistrict Litigation declined to decide, noting that no plaintiff before it had alleged a T-cell lymphoma other than cutaneous T-cell lymphoma or one of its subtypes, and that any expansion could be handled later through the conditional transfer process under Panel Rule 7.1.
In plain terms: peripheral T-cell lymphoma and systemic ALCL are not inside the MDL today, though they may be evaluated individually for conditional transfer. Non-Hodgkin lymphoma of the B-cell type and Hodgkin lymphoma fall outside the litigation entirely.
Warning Signs of CTCL After Dupixent Treatment
Talk to a dermatologist about a biopsy if you notice persistent scaly patches that resemble eczema but never clear, severe itching or burning that does not respond to standard treatment, new skin lesions or tumors, thickened skin on the palms and soles, swollen lymph nodes, hair loss, unexplained weight loss, or night sweats.
Who Qualifies to File a Dupixent Skin Cancer Lawsuit
Dupixent Lymphoma Claims
Check If You Have a Case
Six questions. No cost, no obligation, and nothing you answer here is a legal opinion about your claim.
Month and year is close enough. Leave either blank if you do not remember.
Answer the first two questions to see a result.
Submitting this form does not create an attorney-client relationship. Deadlines to file vary by state and can be short.
Whether you’re eligible to file a Dupixent lawsuit requires three things
- Documented Dupixent use
- Qualifying diagnosis
- A timeline that connects the two.
A free case review is the fastest way to determine eligibility.
You may have a Dupixent lawsuit if you meet the following criteria:
- You were prescribed and used Dupixent (dupilumab), whether for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, or prurigo nodularis
- You were later diagnosed with cutaneous T-cell lymphoma or one of its subtypes, including mycosis fungoides or Sézary syndrome
- Your diagnosis followed the start of Dupixent treatment rather than preceding it
- You can document the treatment and diagnosis dates through medical records
- You are within your state’s filing deadline, or the discovery rule may apply
- You are a surviving spouse, child, parent, or personal representative bringing a claim for families pursuing a wrongful death claim after losing a loved one
The records that move a claim fastest are the ones patients can often gather themselves:
- Pharmacy fill history showing Dupixent prescriptions and dates
- Dermatology and oncology treatment records
- Biopsy and pathology reports establishing the CTCL diagnosis
- Records of any prior skin condition diagnosis predating Dupixent
- Documentation of out-of-pocket treatment costs
- Employment records supporting lost wages or lost earning capacity
If you are missing some of these, that is not a barrier. We obtain records on behalf of clients as a routine part of intake. You can start a free Dupixent lawsuit case review without gathering evidence first.
How to File a Dupixent Lawsuit
You do not need to understand litigation to file a Dupixent lawsuit. The legal process for plaintiffs is short. Our lawyers handle everything.
- Call for a free review. We confirm your diagnosis, when you took Dupixent, and how long you have left to file.
- We collect your medical records. Pharmacy, dermatology, oncology, and pathology records. You don’t have to get these yourself.
- We check whether your diagnosis qualifies. Your records are reviewed against the medical criteria the MDL is using for cutaneous T-cell lymphoma claims.
- We file in the correct court. Your case is filed where you live. You do not travel.
- Your case joins MDL 3180. It is flagged as a tag-along case and transferred to one judge, Judge Zahid N. Quraishi.
- You complete a plaintiff fact sheet. This is a written summary of your medical history. It is the main thing we will need from you personally. Your case moves forward with the group. Test trials, called bellwethers, come later. Cases that don’t settle can be sent back to your home court for trial.
This litigation is new. There are no verdicts and no settlements yet. That is not a reason to wait, because your filing deadline runs on its own schedule, and missing it ends the claim no matter how strong it is.
Is There a Dupixent Class Action Lawsuit?
No. There isn’t a Dupixent class action lawsuit. There is a Dupixent multidistrict litigation.
Here’s the difference between a Dupixent class action lawsuit and multidistrict litigation:
In a class action, a small group of plaintiffs litigates on behalf of all victims. Compensation is pooled and divided by formula. In multidistrict litigation for pharmaceutical injuries, all injured patients keep their own Dupixent case and damages. Consolidation covers pretrial proceedings only. Your medical history, your stage at diagnosis, and your losses are still evaluated on their own facts, which is why a Dupixent claim inside multidistrict litigation isn’t diluted by the group’s size.
Our Dupixent lawsuit lawyers explain this in detail in our blog: mass tort versus class action lawsuits.
The causes of action pled across In re: Dupixent (Dupilumab) Products Liability Litigation are failure to warn, design defect, negligence, and negligent marketing. Whether or not Sanofi and Regeneron failed to warn patients is the central argument. The drug’s label still doesn’t include a serious risk of CTCL.
Dupixent Lawsuit Settlement Amounts & Potential Compensation
There are no Dupixent settlements yet. Anyone quoting you a Dupixent settlement amount right now is guessing.
However, our Dupixent lawsuit attorneys seek maximum compensation for clients diagnosed with cutaneous lymphoma. We seek compensation for: past and future medical expenses including phototherapy, chemotherapy, targeted therapy, hospitalization, and stem cell transplant costs; lost income and reduced earning capacity; pain and suffering; emotional distress; disfigurement; loss of consortium; funeral and burial costs in wrongful death claims; and punitive damages where a jury finds the manufacturers concealed a known risk.
Your Dupixent settlement will depend on various factors.
- Whether you had a more advanced case, since advanced disease progression has a heavier treatment burden and a worse prognosis than early-stage CTCL.
- How long you used Dupixent before diagnosis affects the strength of the argument.
- Age and earning capacity shape the financial losses.
- Whether the case proceeds as a survival action or a wrongful death lawsuit changes both the damages available and who may bring it.
Our Dupixent attorneys assess all of this at intake.
Dupixent Cancer Lawsuit Deadlines and the Statute of Limitations
The statute of limitations is set by state law, not federal court. Taking legal action after a deadline passes ends your case no matter how strong the evidence is.
The Texas personal injury statute of limitations is two years from the date you reasonably should have known your condition was linked to Dupixent use. However, we treat the wrongful death filing deadline in Texas separately because the accrual date is different.
The discovery rule is important for Dupixent users. Here, delayed diagnosis is the pattern in the product liability litigation. Where cutaneous lymphoma was treated as eczema, the argument is that the Dupixent case doesn’t accrue until the patient knew or should have known of the injury and cause. This isn’t a guaranteed extension and isn’t a substitute for filing promptly.
Dupixent Statute of Limitations
Use the state where the patient lived when the lymphoma was diagnosed.
An estimate is fine. This year matters because some states also apply a repose period that runs from the date a product was first sold or supplied.
Cutaneous T-cell lymphoma, mycosis fungoides, Sézary syndrome, or another form of T-cell lymphoma.
Wrongful death claims follow a separate deadline in every state.
This checker is not legal advice; it does not create an attorney-client relationship
Filing Lawsuits For Dupixent-Related Lymphoma Nationwide From Texas
Our legal team handles Dupixent lawsuit claims nationwide. Because legal actions filed anywhere are transferred into one federal court for pretrial proceedings, where you file a Dupixent lawsuit matters less than the attorney handling it.
Your residency determines your filing district and deadline. It doesn’t limit your choice of legal counsel.
Working With Records From Major Cancer Centers
Proving when cutaneous T-cell lymphoma (CTCL) should have been recognized depends on securing medical records and understanding the medical literature surrounding the product liability litigation. Medical records from major academic centers carry real evidentiary weight when reconstructing a diagnosis timeline that spans years of prior eczema treatment. Our Houston office sits beside the Texas Medical Center corridor, one of the country’s principal referral hubs for cutaneous lymphoma, and we are used to working with pathology from institutions of that caliber no matter where the client lives.
Clients in Harris County and the Surrounding Metro
We also represent clients throughout Harris, Fort Bend, Montgomery, Galveston, Brazoria, and Chambers counties, including patients treated at community dermatology practices well outside the Medical Center corridor. Our Harris County personal injury team handles those intakes directly.
National Law Firm For Dupixent Cancer Claims
Patients in every state have contacted us about CTCL diagnoses following Dupixent treatment. We evaluate those Dupixent cases under the law governing where the client lives. Contact our Dupixent lawyers for a free review from anywhere in the country.
Why Patients Diagnosed With CTCL or Subtypes Choose Our Dupixent Lawyers
A Dupixent lawsuit is mass tort litigation against two of the country’s better-resourced pharmaceutical manufacturers, Sanofi and Regeneron. Most law firms aren’t equipped to handle Dupixent’s product liability litigation at scale.
Founding partner Dennis C. Reich has held leadership roles in and produced over $5.5 billion in client recoveries. He served on committees in the Risperdal litigation, a pharmaceutical case built on the same failure-to-warn theory driving MDL 3180.
Committee roles matter. Expert witness and damages committees are where multidistrict litigation is won or lost. That’s exactly where Dupixent lawsuits are headed when drug manufacturers challenge the research on patients’ cutaneous T-cell lymphoma (CTCL) diagnosis.
Mr. Reich tried and won the first diesel exhaust cancer case brought against a railroad in the country. He’s served as lead counsel for thousands of clients exposed to pesticides and industrial solvents who later were diagnosed with cancer. Our attorneys have solved the same evidentiary problem a Dupixent lawsuit presents.
Founding partner Robert J. Binstock has also served on committees in numerous MDLs. Both partners are certified in Personal Injury Trial Law.
Litigation | Result |
|---|---|
$2.8 billion, largest antitrust healthcare settlement ever | |
$2.75 billion, one of the largest non-federal opioid settlements | |
Armstrong World Industries asbestos bankruptcy | Approximately $2.9 billion total recovery |
$626 million partial settlement, ongoing | |
Ongoing | |
BP Deepwater Horizon MDL 2179 | Over $23 million for Houston, METRO, and Harris County |
Harris County v. Juul Labs | $20 million, second-largest governmental entity settlement |
Every Dupixent claim is handled on a contingency fee basis. There are no upfront costs, no hourly rate, and no fee unless we recover for you. You can review our case results and what past clients have said before you call 713-622-7271.
Dupixent Lawsuit FAQs
Is there a Dupixent MDL or class action?
There is an MDL, not a class action. The Judicial Panel on Multidistrict Litigation created MDL No. 3180 in June 2026, and every plaintiff keeps an individual Dupixent lawsuit.
The Dupixent litigation consolidates pretrial processes involving discovery and expert challenges. Your settlement is calculated individually, and unresolved cases can be sent back to your home district for trial.
Call 713-622-7271 to have your Dupixent case reviewed against the current MDL criteria.
Can Dupixent cause lymphoma?
Research shows a Dupixent (dupilumab) and lymphoma risk, not that the drug causes lymphoma specifically. Population-based cohort studies suggest a 4x increased risk of CTCL among Dupixent users, and the FDA’s adverse event data reports have flagged cutaneous T-cell lymphoma subtypes for evaluation.
Causation requires ruling out other medications or concerns, including that the lymphoma was present and misdiagnosed as eczema. This is what MDL NO 3180 is doing.
Contact a Dupixent lawyer for a free case review to determine if you’re eligible to seek compensation.
Does the Dupixent label warn about cancer risks?
No. The FDA-approved prescribing information carries no CTCL or lymphoma warning as of publication.
That absence, alongside a safety signal the FDA has publicly flagged and is still evaluating, is the core of the failure-to-warn allegations. The claim is that patients and prescribing physicians were denied information they needed to make an informed treatment decision.
Bring your prescribing records to a free consultation so we can document what you were told.
Should I stop taking Dupixent if I was diagnosed with cutaneous T-cell lymphoma?
No, if you were prescribed Dupixent, you shouldn’t stop taking it without talking to your doctor first. Legal claims never depend on discontinuing treatment. Seeking compensation doesn’t require you to change your medication.
Talk to your doctor first, then call 713-622-7271.
Can I file a Dupixent lawsuit if I have another cancer diagnosis besides CTCL?
Whether patients treated with Dupixent can file lawsuits depends on their specific condition. The multidistrict litigation currently covers cutaneous T-cell lymphoma (CTCL) diagnoses and common subtypes. Other cancer diagnoses are treated differently and filed individually.
The Judicial Panel on Multidistrict Litigation declined to rule on non-CTCL T-cell lymphomas at centralization, so those legal claims are reviewed individually rather than assumed into the product liability litigation.
Cutaneous T-cell lymphoma subtypes are currently within MDL 3180
Peripheral T-cell lymphoma and anaplastic large cell lymphoma may be evaluated for conditional transfer under Panel Rule 7.1
B-cell lymphoma and Hodgkin’s lymphoma fall outside the current MDL scope
If you or a loved one received a lymphoma diagnosis and aren’t sure whether you’re eligible to file a lawsuit, reach out to a Dupixent lawsuit attorney at our firm for a free review.
How much does a Dupixent attorney cost?
Nothing upfront. Our Dupixent lawyers handle cases on a contingency fee basis, so you don’t pay anything unless we recover compensation on your behalf.
Call 713-622-7271 or request a free case review online.
Contact a Dupixent Lawsuit Attorney For a Free Case Review
If you or a family member was diagnosed with cutaneous T-cell lymphoma after taking Dupixent, you may be eligible to file a Dupixent lawsuit. If you or a loved one developed cutaneous T-cell lymphoma after using Dupixent, contact an experienced attorney from our law firm to schedule a free consultation. We handle claims on a contingency fee basis, so you don’t pay anything unless we win. Call Reich & Binstock at 713-622-7271 or request a free case review online. Do not stop taking Dupixent without consulting your doctor.There is never a fee unless we recover on your behalf.
Additionally, clients are not obligated to pay expenses if a recovery is not made.
